S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
NASDAQ:AMLX

Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis

$2.10
-0.19 (-8.30%)
(As of 04/12/2024 ET)
Today's Range
$2.07
$2.29
50-Day Range
$2.29
$19.57
52-Week Range
$2.07
$31.77
Volume
2.82 million shs
Average Volume
2.91 million shs
Market Capitalization
$142.34 million
P/E Ratio
3.00
Dividend Yield
N/A
Price Target
$32.67

Amylyx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
1,455.6% Upside
$32.67 Price Target
Short Interest
Bearish
12.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.09mentions of Amylyx Pharmaceuticals in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$193,098 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.01) to ($1.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.54 out of 5 stars

Medical Sector

898th out of 2,784 stocks

Pharmaceutical Preparations Industry

379th out of 1,293 stocks

AMLX stock logo

About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

AMLX Stock Price History

AMLX Stock News Headlines

My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
Unveiling 6 Analyst Insights On Amylyx Pharma
See More Headlines
Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/12/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMLX
Fax
N/A
Employees
384
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.67
High Stock Price Target
$48.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+1,384.8%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$49.27 million
Pretax Margin
14.26%

Debt

Sales & Book Value

Annual Sales
$380.79 million
Cash Flow
$0.54 per share
Book Value
$6.42 per share

Miscellaneous

Free Float
59,784,000
Market Cap
$149.12 million
Optionable
Optionable
Beta
-0.93
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Joshua B. Cohen (Age 32)
    Co-Founder, Co-CEO & Director
    Comp: $1M
  • Mr. Justin B. Klee (Age 33)
    Co-Founder, Co-CEO & Director
    Comp: $1M
  • Mr. James M. Frates M.B.A. (Age 57)
    Chief Financial Officer
    Comp: $695.12k
  • Ms. Gina M. Mazzariello (Age 53)
    Chief Legal Officer & General Counsel
    Comp: $794.83k
  • Mr. Tom Holmes
    Chief Technical Operations Officer
  • Lindsey Allen
    Head of Investor Relations & Communications
  • Ms. Shauna Horvath
    Head of Global Marketing
  • Ms. Linda A. Arsenault
    Chief Human Resources Officer
  • Mr. Chris Aiello
    Head of Canada & GM
  • Mr. Keith White
    Head of Global Market Access

AMLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Amylyx Pharmaceuticals stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMLX, but not buy additional shares or sell existing shares.
View AMLX analyst ratings
or view top-rated stocks.

What is Amylyx Pharmaceuticals' stock price target for 2024?

8 Wall Street analysts have issued 12 month price targets for Amylyx Pharmaceuticals' shares. Their AMLX share price targets range from $8.00 to $48.00. On average, they expect the company's stock price to reach $32.67 in the next twelve months. This suggests a possible upside of 1,455.6% from the stock's current price.
View analysts price targets for AMLX
or view top-rated stocks among Wall Street analysts.

How have AMLX shares performed in 2024?

Amylyx Pharmaceuticals' stock was trading at $14.72 on January 1st, 2024. Since then, AMLX stock has decreased by 85.7% and is now trading at $2.10.
View the best growth stocks for 2024 here
.

When is Amylyx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our AMLX earnings forecast
.

How were Amylyx Pharmaceuticals' earnings last quarter?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) released its quarterly earnings results on Thursday, February, 22nd. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of $0.20 by $0.03. The company earned $108.45 million during the quarter, compared to analysts' expectations of $106.40 million. Amylyx Pharmaceuticals had a net margin of 12.94% and a trailing twelve-month return on equity of 12.39%. During the same quarter last year, the business posted ($0.65) earnings per share.

What ETFs hold Amylyx Pharmaceuticals' stock?
When did Amylyx Pharmaceuticals IPO?

Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share.

How do I buy shares of Amylyx Pharmaceuticals?

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMLX) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners